Navamedic ASA – Approval and publication of listing prospectus of Observe Medical ASA

Report this content

Navamedic ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the "Listing") and the completion of the demerger of NAVA, respectively.

The prospectus for the Listing (the "Prospectus") was approved by the Financial Supervisory Authority of Norway today, on 1 November 2019. The Prospectus has been published today and is available at

Observe Medical's shares will be listed on Oslo Axess on Monday 4 November 2019. Hard copies of the Prospectus may be obtained by contacting Observe Medical.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680

Toril Ås, CFO, Navamedic
Mobile: +47 957 01 071

About Navamedic ASA:
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit


Documents & Links